CytomX is creating a new generation of highly targeted antibody therapeutics that significantly expand the target space for this class of drugs, drive efficacy and deliver improved safety profiles.
CytomX’s Probody™ Platform precisely targets the disease microenvironment in ways that have not been possible to-date, enabling a new level of tissue activation and selectivity that enables access to new targets and expands the therapeutic index of current antibody therapeutics.
This proprietary platform is driving the development of a pipeline of fully recombinant, protease-activated monoclonal antibodies, called Probodies, with unparalleled targeting and efficacy. Probodies expand the therapeutic index for targets that have validated disease biology, but also display normal tissue expression patterns that are too widespread to allow for adequate safety margins using conventional antibody approaches.
CytomX’s Probody Platform and pipeline of Probodies are based on a robust portfolio of intellectual property and patented technology.